Abstract Number: 869 • 2016 ACR/ARHP Annual Meeting
Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is the most frequent inflammatory disorder in persons older than 50 years of age. Biomarkers like ESR and CRP may be…Abstract Number: 1638 • 2016 ACR/ARHP Annual Meeting
Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients
Background/Purpose: Methotrexate (MTX) is the first line treatment for Rheumatoid Arthritis (RA) in Sweden, but one third of patients do not experience satisfying treatment response.…Abstract Number: 2135 • 2016 ACR/ARHP Annual Meeting
Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation
Background/Purpose: Osteoarthritis (OA) is a disease characterized by pain and tissue destruction, in some cases concomitant with inflammation. The link between pain and tissue destruction…Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…Abstract Number: 3035 • 2016 ACR/ARHP Annual Meeting
Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease that affects over 650,000 Americans. Bone damage occurs in half of these patients within the first…Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…Abstract Number: 914 • 2016 ACR/ARHP Annual Meeting
Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Background/Purpose: SLE is a systemic autoimmune disease that predominantly affects women in reproductive years. SLE pregnancies result in higher rates of adverse outcomes compared with…Abstract Number: 1652 • 2016 ACR/ARHP Annual Meeting
Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which…Abstract Number: 2136 • 2016 ACR/ARHP Annual Meeting
CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model
Background/Purpose: CD14, though expressed by multiple cell types, is highly expressed by monocytes and macrophages. It forms a complex with Toll-like receptors (TLRs), particularly TLR-2…Abstract Number: 2619 • 2016 ACR/ARHP Annual Meeting
Sustained Suppression of Peripheral Biomarkers By Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in the Phase IIb Earth Explorer 2 Clinical Trial
Background/Purpose: Treatment of rheumatoid arthritis (RA) patients by anti-tumour necrosis factors (anti-TNFs), such as golimumab, has improved patient outcomes. However, unmet therapeutic needs exist for…Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting
Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…Abstract Number: 380 • 2016 ACR/ARHP Annual Meeting
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…Abstract Number: 1656 • 2016 ACR/ARHP Annual Meeting
Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Background/Purpose: Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data…Abstract Number: 2291 • 2016 ACR/ARHP Annual Meeting
Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease
Background/Purpose: Gout and hyperuricemia have been associated with cardiovascular disease. Studies have documented the impact of serum urate levels on hypertension and that increased urate…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 83
- Next Page »